Pages that link to "Property:P94"
Jump to navigation
Jump to search
The following pages link to occurs in (P94):
View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)- 1st paragraph(s) in Introduction (From DOI: 10.3390/v12030254) (Q7860) (← links)
- 2nd paragraph(s) in Introduction (From DOI: 10.3390/v12030254) (Q7861) (← links)
- 3rd paragraph(s) in Introduction (From DOI: 10.3390/v12030254) (Q7862) (← links)
- 4th paragraph(s) in Introduction (From DOI: 10.3390/v12030254) (Q7863) (← links)
- 5th paragraph(s) in Introduction (From DOI: 10.3390/v12030254) (Q7864) (← links)
- 1st paragraph(s) in Materials and Methods: Acquisition and Processing of Sequence Data section (From DOI: 10.3390/v12030254) (Q7865) (← links)
- 1st paragraph(s) in Materials and Methods: Acquisition and Filtering of Epitope Data section (From DOI: 10.3390/v12030254) (Q7866) (← links)
- 1st paragraph(s) in Materials and Methods: Population-Coverage-Based T Cell Epitope Selection section (From DOI: 10.3390/v12030254) (Q7867) (← links)
- 1st paragraph(s) in Materials and Methods: Constructing the Phylogenetic Tree section (From DOI: 10.3390/v12030254) (Q7868) (← links)
- 1st paragraph(s) in Materials and Methods: Data and Code Availability section (From DOI: 10.3390/v12030254) (Q7869) (← links)
- 1st paragraph(s) in Results: Structural Proteins of SARS-CoV-2 Are Genetically Similar to SARS-CoV, but Not to MERS-CoV section (From DOI: 10.3390/v12030254) (Q7870) (← links)
- 2nd paragraph(s) in Results: Structural Proteins of SARS-CoV-2 Are Genetically Similar to SARS-CoV, but Not to MERS-CoV section (From DOI: 10.3390/v12030254) (Q7871) (← links)
- 1st paragraph(s) in Results: Mapping the SARS-CoV-Derived T Cell Epitopes That Are Identical in SARS-CoV-2, and Determining Those with Greatest Estimated Population Coverage section (From DOI: 10.3390/v12030254) (Q7872) (← links)
- 2nd paragraph(s) in Results: Mapping the SARS-CoV-Derived T Cell Epitopes That Are Identical in SARS-CoV-2, and Determining Those with Greatest Estimated Population Coverage section (From DOI: 10.3390/v12030254) (Q7873) (← links)
- 1st paragraph(s) in Results: Mapping the SARS-CoV-Derived B cell Epitopes that Are Identical in SARS-CoV-2 section (From DOI: 10.3390/v12030254) (Q7874) (← links)
- 2nd paragraph(s) in Results: Mapping the SARS-CoV-Derived B cell Epitopes that Are Identical in SARS-CoV-2 section (From DOI: 10.3390/v12030254) (Q7875) (← links)
- 3rd paragraph(s) in Results: Mapping the SARS-CoV-Derived B cell Epitopes that Are Identical in SARS-CoV-2 section (From DOI: 10.3390/v12030254) (Q7876) (← links)
- 4th paragraph(s) in Results: Mapping the SARS-CoV-Derived B cell Epitopes that Are Identical in SARS-CoV-2 section (From DOI: 10.3390/v12030254) (Q7877) (← links)
- 5th paragraph(s) in Results: Mapping the SARS-CoV-Derived B cell Epitopes that Are Identical in SARS-CoV-2 section (From DOI: 10.3390/v12030254) (Q7878) (← links)
- 6th paragraph(s) in Results: Mapping the SARS-CoV-Derived B cell Epitopes that Are Identical in SARS-CoV-2 section (From DOI: 10.3390/v12030254) (Q7879) (← links)
- 1st paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7880) (← links)
- 2nd paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7881) (← links)
- 3rd paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7882) (← links)
- 4th paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7883) (← links)
- 5th paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7884) (← links)
- 6th paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7885) (← links)
- 7th paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7886) (← links)
- 8th paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7887) (← links)
- 9th paragraph(s) in Discussion section (From DOI: 10.3390/v12030254) (Q7888) (← links)
- Introduction section from DOI: 10.3390/pathogens9020148 (Q7903) (← links)
- Novel Coronavirus 2019-nCoV section from DOI: 10.3390/pathogens9020148 (Q7904) (← links)
- Transmission and Symptoms section from DOI: 10.3390/pathogens9020148 (Q7905) (← links)
- Perspectives on Biopharmaceuticals Development section from DOI: 10.3390/pathogens9020148 (Q7906) (← links)
- Concluding Remarks section from DOI: 10.3390/pathogens9020148 (Q7907) (← links)
- Table 1 - Advantages and disadvantages of different therapeutic protein production platforms (From DOI: 10.3390/pathogens9020148) (Q7908) (← links)
- Table 2 - Examples of recombinant antigens and monoclonal antibodies expressed in plants (From DOI: 10.3390/pathogens9020148) (Q7909) (← links)
- Author Contributions (From DOI: 10.3390/pathogens9020148) (Q7910) (← links)
- Acknowledgments (From DOI: 10.3390/pathogens9020148) (Q7911) (← links)
- Conflicts of Interest (From DOI: 10.3390/pathogens9020148) (Q7912) (← links)
- Full Bibliography (From DOI: 10.3390/pathogens9020148) (Q7913) (← links)
- License Statement (From DOI: 10.3390/pathogens9020148) (Q7915) (← links)
- Introduction (Main section from DOI: 10.7326/m20-0504) (Q7922) (← links)
- Methods: Data Collection (Subsection from DOI: 10.7326/m20-0504) (Q7923) (← links)
- Methods: Statistical Analysis (Subsection from DOI: 10.7326/m20-0504) (Q7924) (← links)
- Methods: Role of the Funding Source (Subsection from DOI: 10.7326/m20-0504) (Q7925) (← links)
- Results (Main section from DOI: 10.7326/m20-0504) (Q7926) (← links)
- Discussion (Main section from DOI: 10.7326/m20-0504) (Q7927) (← links)
- Table 1 - Characteristics of Patients With Confirmed COVID-19 Included in This Analysis (n = 181)* (From DOI: 10.7326/m20-0504) (Q7928) (← links)
- Table 2 - Expected Number of Symptomatic SARS-CoV-2 Infections That Would Be Undetected During Active Monitoring, Given Varying Monitoring Durations and Risks for Symptomatic Infection After Exposure* (From DOI: 10.7326/m20-0504) (Q7929) (← links)
- Figure 1 - SARS-CoV-2 exposure (blue), symptom onset (red), and case detection (green) times for 181 confirmed cases. (From DOI: 10.7326/m20-0504) (Q7930) (← links)
